RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Prince Harry embarks on a new courtroom battle against British tabloids in his case against Rupert Murdoch’s News Group ...

Robert F. Kennedy Jr. will be pulling his investments from two biotechs if he is confirmed to lead the U.S. Department of ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

The research teams at LV Prasad Eye Institute under the Centre for Ocular Regeneration (CORE) at the Brien Holden Research Centre, organized the second edition of the ‘Future is Here’.

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...